Shares of Everest Medicines Limited (HKG:1952) soared 7.62% on October 25th, capping a remarkable 41% gain over the past week. This surge benefited the company's largest shareholder group - retail investors who collectively own 46% of the outstanding shares.
The stock's rally allowed retail investors to reap substantial gains on their investments. With such a significant ownership stake, their trading activity likely fueled the upward momentum as they capitalized on positive sentiment surrounding the biopharmaceutical company.
Beyond retail investors, Everest Medicines has a diverse ownership base. Institutional investors hold a 12% stake, while insiders own less than 1% of shares. Private equity firms also maintain a considerable 41% ownership position, giving them influence over corporate strategy. This varied investor mix contributed to the stock's impressive performance amid heightened demand.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.